ClinicalTrials.gg
Not yet recruitingNCT07620405Updated Jun 4, 2026

Open-Label Extension Study of MHB018A in Patients With Thyroid Eye Disease

A Phase 3 interventional study of MHB018A injection in Thyroid Eye Disease (TED), sponsored by Minghui Pharmaceutical (Hangzhou) Ltd. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Minghui Pharmaceutical (Hangzhou) Ltd (part of Minghui Pharmaceutical) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
219
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a multicenter, open-label extension (OLE) study of MHB018A in subjects with moderate-to-severe TED.

Read the detailed description

The primary objective of this study is to evaluate the improvement in proptosis from baseline (defined as the most recent measurement prior to the first dose in this study) following treatment with MHB018A Injection in subjects with active or chronic TED who previously received placebo in either the MHB018A-P-304 or MHB018A-P-305 studies, and the safety and tolerability of MHB018A Injection in TED subjects.

02

Conditions studied

  • Thyroid Eye Disease (TED)

Browse trials for

03

In context

Graves Ophthalmopathy

199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.

This study's planned enrollment of 219 is above the median of 63 across 146 interventional studies indexed under Graves Ophthalmopathy.

Browse Graves Ophthalmopathy studies →

Lead sponsor

Minghui Pharmaceutical (Hangzhou) Ltd is the lead sponsor of 20 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects voluntarily participating in the study and signing the form;
  2. Aged 18-75 years (inclusive), of any gender;
  3. Completed the 24-week double-blind treatment period in either the MHB018A-P-301 or MHB018A-P-302 study, and within 28 days after Week 24 visit of the previous study when enrolled in this OLE study (does not apply to subjects who meet the relapse criteria during the safety follow-up period).
  4. Proptosis non-responder at Week 24 visit in the double-blind treatment period of either the MHB018A-P-301 or MHB018A-P-302 study (defined as a \<2 mm reduction from baseline in the study eye, or a ≥2 mm reduction in the study eye accompanied by a ≥2 mm worsening from baseline in proptosis of the fellow eye), and/or who meet the retreatment criteria for relapse during the safety follow-up period.
  5. Does not require immediate surgical ophthalmological intervention, and no corrective surgery/orbital radiotherapy is planned during the study.
  6. Diabetic subjects must have well-controlled stable disease.
  7. Sufficient bone marrow and organ function.
  8. Eligible subjects of (male and female) must agree to use reliable methods; female subjects of childbearing potential must have a negative blood pregnancy test within 7 days before the first use of the study drug and must not be breastfeeding.
  9. Subject is willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the study.

    -

Exclusion criteria

Exclusion Criteria:

  1. Decreased best corrected visual acuity due to optic neuropathy as defined by a decrease in vision within the last 6 months of two lines of Snellen chart, new visual field defect or color defect secondary to optic nerve involvement.
  2. Corneal decompensation unresponsive to medical management.
  3. Free thyroxine (FT4) and free triiodothyronine (FT3) levels \<50% above or below the normal reference range at screening.
  4. Received any treatment for TED, intravenous , agents, drug from the last visit of the MHB018A-P-301 or MHB018A-P-302 trial until participation in this study.
  5. Identified pre-existing ophthalmic disease that would preclude study participation or complicate interpretation of the study results.
  6. Acute cardiovascular disease history or treatment within 6 months before the first dose from the last visit of the MHB018A-P-301 or MHB018A-P-302 trial until participation in this study.
  7. Presence of poorly controlled hypertension with systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg; Renal artery stenosis.
  8. Pregnant or lactating women.
  9. Tinnitus or other hearing impairment.
  10. Poor compliance or severe systemic disease history or other reasons that make the subject unsuitable for participation in this clinical study.

    -

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
219 participants (estimated)

Study arms

  • Experimental
    MHB018A Injection

    Subcutaneous injections of MHB018A injection, 450mg once every 4 weeks (q4w).

    Drug: MHB018A injection

Interventions

  • MHB018A 450mg for subcutaneous injection once every 4 weeks (Q4W)

06

What researchers measure

Primary outcomes

  1. Proptosis Responder Rate at Week 24

    The proptosis response rate at Week 24 in the study eye for subjects with active or chronic TED who received MHB018A placebo in either the MHB018A-P-301 or MHB018A-P-302 studies: the proportion of subjects achieving a reduction of ≥2 mm in proptosis from baseline (defined as the most recent measurement prior to the first dose in this study) in the study eye, without deterioration in the other eye (defined as an increase in proptosis of ≥2 mm).

    Time frame: Week 24

Secondary outcomes

  1. TED relapse rate

    TED relapse rate from treatment discontinuation to relapse (for subjects with active or chronic TED who previously received and completed 24 weeks of MHB018A Injection treatment in either the MHB018A-P-301 or MHB018A-P-302 study, meet the disease relapse enrollment criteria for this study during the safety follow-up period, and receive retreatment with MHB018A Injection)

    Time frame: From baseline up to Week 24

  2. TED relapse time

    TED relapse time from treatment discontinuation to relapse (for subjects with active or chronic TED who previously received and completed 24 weeks of MHB018A Injection treatment in either the MHB018A-P-301 or MHB018A-P-302 study, meet the disease relapse enrollment criteria for this study during the safety follow-up period, and receive retreatment with MHB018A Injection)

    Time frame: Up to Week 24 and at end-of-trial (EOT) visit

  3. Overall response rate

    The percentage of subjects with ≥2-points in Clinical Activity Score (CAS) reduction and ≥2 mm reduction in proptosis from baseline, provided there is no corresponding deterioration (≥2-points/mm increase) in CAS or proptosis in the fellow eye.

    Time frame: Week 24

  4. Change in proptosis

    Change from baseline in proptosis in the study eye as measured by exophthalmometer at Week 24

    Time frame: Baseline, up to Week 24

  5. Percentage of subjects with CAS of 0 or 1

    The percentage of subjects with a CAS (Clinical Activity Score) of 0 or 1 in the study eye/target eye. CAS ranges from 0 to 7, while higher scores mean a worse outcome.

    Time frame: Week 24

  6. Change in CAS

    The mean change from baseline to Week 24 in the CAS (Clinical Activity Score) in the study eye/target eye. CAS ranges from 0 to 7, while higher scores mean worse outcome.

    Time frame: Week 24

  7. Diplopia response rate

    The percentage of subjects with a reduction in diplopia severity by ≥1 grade.

    Time frame: Week 24

  8. Change in Quality of Life (GO-QOL) Scores

    The mean change in scores from the Graves' Ophthalmopathy Quality of Life questionnaire compared to baseline. The GO-QoL is a self-filled questionnaire containing 16 items. The raw scores for items 1-8 and items 9-16 are summed separately, each yielding a total raw score ranging from 8 to 24. Each raw score is then transformed into a 0-100 scale using the following formula: Total Score = (Raw Score - 8) ÷ 16 × 100. Higher scores indicate better quality of life.

    Time frame: Up tp Week 24

  9. Pharmacokinetic Parameter Trough Concentration for MHB018A

    Trough concentration (Ctrough) will be assessed using non-compartmental methods in participants randomized to the MHB018A group.

    Time frame: Up tp Week 24

  10. Incidence of Adverse Events (AEs) During Treatment

    Including Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and AEs leading to early study withdrawal, along with laboratory tests, 12-lead ECGs, vital signs, and physical examinations.

    Time frame: Up to Week 24 and at end-of-trial (EOT) visit

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2027; primary completion for Jan 2030, 30 months later.

Of 29 phase 3 interventional studies under Graves Ophthalmopathy, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 25. This study's planned 30 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2026
First posted
Jun 2, 2026
StartEst.
Jul 2027
Primary completionEst.
Jan 2030
CompletionEst.
Jan 2031
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07620405
Responsible party
Sponsor
First posted
Jun 2, 2026
Start date
Jul 2027 (estimated)
Primary completion
Jan 2030 (estimated)
Completion
Jan 2031 (estimated)
Last update
Jun 4, 2026

Study contacts

CMO/ Senior Vice President of R&D
Contact
jwshi@minghuipharma.com
86 0571-86963293

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MHB018A

Start the discussion